ARTICLE | Clinical News
Budesonide rectal foam regulatory update
February 3, 2014 8:00 AM UTC
Salix said FDA accepted for review an NDA for budesonide 2 mg rectal foam for induction of remission in patients with active mild to moderate ulcerative colitis (UC) extending up to 40 cm from the ana...